Articles |
Correspondence to Dr A.F.H. Stalenhoef, Department of Medicine, Division of General Internal Medicine 541, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, the Netherlands. E-mail A.Stalenhoef@aig.azn.nl
| Introduction |
|---|
Dr Jonathan C. Fox from the University of Pennsylvania, Philadelphia, opened the meeting with a state-of-the-art lecture entitled "Cardiovascular Gene Therapy: Current Concepts." Gene therapy constitutes a novel therapeutic approach to selected cardiovascular diseases and is designed to augment traditional techniques of diagnosis and treatment by targeting the molecular mechanisms of disease.
Dr Fox first presented the general strategies driving the development of gene therapy. In the case of deleterious gene mutations causing disease, the defective gene can be replaced with a normal copy. In a pathophysiologic process that can be alleviated through augmented gene function, a beneficial gene can be overexpressed or a mutated "designer" gene, which is either more active or in some way more beneficial than its natural precursor, can be expressed. Normal genes may also confer therapeutic benefits by virtue of their expression in a novel environment. The expression of harmful genes can also be inhibited by antisense oligonucleotides, antisense RNA expression vectors, ribozymes, or triplex DNA. Dominant negative genes can be expressed, eg, encoding a protein that binds to regulatory partners but is not active. So-called decoy DNA, made up of short segments of double-stranded DNA encoding the recognition sequence for regulatory proteins such as transcription factors, can be delivered to cells, binding the transcription factors and, thereby, competing for their biologic targets and inhibiting their function.
The requirements for
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |